LITH (BioELife) Debt-to-EBITDA : 0.00 (As of Sep. 2019)


What is BioELife Debt-to-EBITDA?

BioELife LITH -99.00% Debt-to-EBITDA is 0.00 as of Sep. 2019.

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioELife's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.00 Mil. BioELife's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.00 Mil. BioELife's annualized EBITDA for the quarter that ended in Sep. 2019 was $-0.19 Mil. BioELife's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2019 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioELife's Debt-to-EBITDA or its related term are showing as below:

LITH's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

BioELife  (OTCPK:LITH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

BioELife Debt-to-EBITDA Related Terms

BioELife Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for BioELife's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioELife Debt-to-EBITDA Chart

BioELife Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 -1.56 -1.64 -2.22 -1.10

BioELife Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 -0.14 0.80 0.00 0.00

LITH vs BSPK, PCYN, CNABQ: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioELife's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioELife Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioELife's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioELife's Debt-to-EBITDA falls into.


BioELife Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioELife's Debt-to-EBITDA for the fiscal year that ended in Dec. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.28 + 0) / -0.254
=-1.10

BioELife's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2019 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.188
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2019) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
BioELife (LITH) has a Debt-to-EBITDA of 0.00 as of Sep. 2019. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioELife.
Is BioELife's Debt-to-EBITDA too high?
BioELife's current Debt-to-EBITDA is 0.00.
How does BioELife's Debt-to-EBITDA compare to BSPK and PCYN?
BioELife's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioELife. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioELife's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioELife stock overvalued right now?
BioELife (LITH) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioELife (LITH), the current Debt-to-EBITDA is 0.00 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioELife Business Description

Address 12340 Seal Beach Boulevard, Suite B-190, Seal Beach, CA, USA, 90740
BioELife Corp is engaged in the manufacturing and distribution of Cannabinoid products. The company's product portfolio includes Combo Adult Gummies with Chirorub; Combo Tincture with Chirorub; Intensive Relief Rub; Tinctures; Adult Gummies; Premium Pre-Rolls; and Flower.